Enliven Therapeutics, Inc. ELVN
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 15.09% | -45.28% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 33.73% | -18.85% | |||
| Operating Income | -33.73% | 18.85% | |||
| Income Before Tax | -37.49% | 20.36% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -37.49% | 20.36% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -37.49% | 20.36% | |||
| EBIT | -33.73% | 18.85% | |||
| EBITDA | -33.78% | 18.78% | |||
| EPS Basic | -30.49% | 21.12% | |||
| Normalized Basic EPS | -30.50% | 21.11% | |||
| EPS Diluted | -30.49% | 21.12% | |||
| Normalized Diluted EPS | -30.50% | 21.11% | |||
| Average Basic Shares Outstanding | 5.37% | 0.94% | |||
| Average Diluted Shares Outstanding | 5.37% | 0.94% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||